


### Listing of the Claims:

The following listing of claims will replace all prior versions and listings of claims in the application.

1-12. (Canceled)

13. (Previously Presented) A vaccine for preventing viral infections comprising:  
an antigen;  
a peptide (Peptide A) comprising a sequence  $R_1\text{-XZXX}_N\text{XZX-R}_2$ , whereby N is a whole number between 3 and 7, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and  $R_1$  and  $R_2$  are independently -H, -NH<sub>2</sub>, -COCH<sub>3</sub>, -COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide;  $X\text{-R}_2$  is an amide, ester or thioester of the C-terminal amino acid residue of the peptide; and  
an immunostimulatory oligodeoxynucleic acid molecule (I-/U-ODN) having the structure according to the formula (I):



wherein:

R1 is selected from hypoxanthine and uracile;

any X is O or S;

any NMP is a 2' deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-,

deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate;

NUC is a 2' deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyinosine-, deoxythymidine-, 2-methyl-deoxyuridine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine;

a and b are integers from 0 to 100 with the proviso that a + b is between 4 and 150; and

B and E are common groups for 5' or 3' ends of nucleic acid molecules.

14. (Previously Presented) The vaccine of claim 13, wherein N is 5.
15. (Previously Presented) The vaccine of claim 13, further comprising an  $\text{Al}(\text{OH})_3$  adjuvant.
16. (Previously Presented) The vaccine of claim 13, wherein the antigen is a viral antigen.
17. (Previously Presented) The vaccine of claim 16, wherein the viral antigen is an influenza virus antigen, HCV antigen, HBV antigen, HIV antigen, HPV antigen, JEV antigen, a combined antigen, or a combination of one or more of these antigens.
18. (Previously Presented) The vaccine of claim 18, wherein the viral antigen is an influenza antigen further defined as a haemagglutinin antigen or a neuraminidase antigen.
19. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide.
20. (Previously Presented) The vaccine of claim 13, wherein Peptide A is  $\text{KLKL}_5\text{KLK}$  and the I-/U-ODN is oligo d(IC)<sub>13</sub>.

21. (Previously Presented) The vaccine of claim 13, further comprising an oligodeoxynucleotide containing a CpG-motif.

22. (Previously Presented) The vaccine of claim 13, further comprising a polycationic peptide and an oligodeoxynucleotide containing a CpG-motif.

23.-28. (Canceled)